Compare DCTH & ASPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCTH | ASPI |
|---|---|---|
| Founded | 1988 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.4M | 507.5M |
| IPO Year | 2015 | 2022 |
| Metric | DCTH | ASPI |
|---|---|---|
| Price | $15.41 | $2.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $24.00 | $13.00 |
| AVG Volume (30 Days) | 281.2K | ★ 3.7M |
| Earning Date | 11-03-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.53 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $23,849,000.00 |
| Revenue This Year | $24.61 | N/A |
| Revenue Next Year | $24.27 | $243.14 |
| P/E Ratio | $396.00 | ★ N/A |
| Revenue Growth | N/A | ★ 475.48 |
| 52 Week Low | $8.12 | $2.51 |
| 52 Week High | $17.42 | $14.49 |
| Indicator | DCTH | ASPI |
|---|---|---|
| Relative Strength Index (RSI) | 49.59 | 27.99 |
| Support Level | $15.68 | N/A |
| Resistance Level | $16.51 | $4.45 |
| Average True Range (ATR) | 0.43 | 0.17 |
| MACD | -0.09 | -0.04 |
| Stochastic Oscillator | 48.67 | 12.50 |
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
ASP Isotopes Inc is a materials company focused on producing and commercializing enriched isotopes for the nuclear medicine, healthcare, green energy, and quantum computing industries. Currently, the company has three operating segments: (i) nuclear fuels, (ii) specialist isotopes and related services, and (iii) construction services. Using proprietary technology-the Aerodynamic Separation Process (ASP)-the company enriches isotopes in South Africa, targeting high-value, low-volume markets to reduce reliance on foreign supply chains. Geographically, the company operates in South Africa, Hong Kong and United States generating key revenue from the Hong Kong region.